Albireo to Report Q2 2022 Financial Results on August 15, 2022
August 01 2022 - 8:30AM
Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company
developing novel bile acid modulators, today announced that
management will host a conference call and live audio webcast
at 4:30 p.m. ET on August 15, 2022, to provide a business
update and review the company’s financial results for the quarter
ended June 30, 2022.
To access the live conference call by phone, dial
1-855-327-6837 (domestic) or 1-631-891-4304 (international),
and provide the access code 10019926. A live audio webcast will be
accessible from the Investors page at ir.albireopharma.com/.
To ensure a timely connection to the webcast, it is recommended
that participants register at least 15 minutes prior to the
scheduled start time. An archived version of the webcast will be
available for replay on the Events & Presentations section of
the Investors page of Albireo’s website for 3 months following the
event.
About Albireo
Albireo Pharma is a rare disease company focused on the
development of novel bile acid modulators to treat rare pediatric
and adult liver diseases. Albireo’s lead product, Bylvay, was
approved by the U.S. FDA as the first drug for the treatment of
pruritus in all types of progressive familial intrahepatic
cholestasis (PFIC), and in Europe, Bylvay has been approved
for the treatment of PFIC. Bylvay is also being developed to treat
other rare pediatric cholestatic liver diseases with global Phase 3
trials in Alagille syndrome (ALGS) and biliary atresia, as well as
Open-label Extension (OLE) studies for PFIC and ALGS. The Company
has also completed a Phase 1 clinical trial for A3907 to advance
development in adult cholestatic liver disease, with IND-enabling
studies progressing with A2342 for viral and cholestatic liver
disease. Albireo was spun out from AstraZeneca in 2008 and is
headquartered in Boston, Massachusetts, with its key operating
subsidiary in Gothenburg, Sweden. For more information on Albireo,
please visit www.albireopharma.com.
Media Contact:Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.comLance Buckley,
917-439-2241, lbuckley@lippetaylor.com
Investor Contact:Hans Vitzthum, LifeSci
Advisors, LLC., 617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Sep 2023 to Sep 2024